Patents by Inventor Andrew Mark Thompson

Andrew Mark Thompson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11931801
    Abstract: A multi-grain selector device includes an outer body having exterior surfaces. The outer body includes a cooling side configured to face a cooling plate of a casting furnace and an opposite mold side configured to face into a mold. The outer body includes an array of multiple grain selector columns each formed from two or more transversely oriented, elongated channels that are fluidly coupled with each other in an end-to-end arrangement oriented along a growth direction that extends from the cooling side of the outer body toward the mold side of the outer body. The selector columns extend to growth openings on the mold side of the outer body. Each of the selector columns is configured to form a single grain column out of the corresponding growth opening that is part of a columnar grained article to be formed in the mold that grows along the growth direction.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: March 19, 2024
    Assignee: GE INFRASTRUCTURE TECHNOLOGY LLC
    Inventors: Anthony Mark Thompson, Andrew Fox Thompson, Judson Sloan Marte
  • Patent number: 9198913
    Abstract: The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: December 1, 2015
    Assignee: Global Alliance for TB Drug Development
    Inventors: William Alexander Denny, Andrew Mark Thompson, Adrian Blaser, Zhenkun Ma, Brian Desmond Palmer, Hamish Scott Sutherland, Iveta Kmentova
  • Patent number: 8293734
    Abstract: The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: October 23, 2012
    Assignee: Global Alliance for TB Drug Development
    Inventors: Andrew Mark Thompson, William Alexander Denny, Adrian Blaser, Zhenkun Ma
  • Publication number: 20120028973
    Abstract: The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Application
    Filed: July 30, 2010
    Publication date: February 2, 2012
    Applicant: Global Alliance for TB Drug Development
    Inventors: William Alexander Denny, Andrew Mark Thompson, Adrian Blaser, Brian Desmond Palmer, Zhenkun Ma, Hamish Scott Sutherland, Iveta Kmentova
  • Publication number: 20110028466
    Abstract: The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.
    Type: Application
    Filed: July 30, 2010
    Publication date: February 3, 2011
    Applicant: Global Alliance for TB Drug Development
    Inventors: Andrew Mark Thompson, William Alexander Denny, Adrian Blaser, Zhenkun Ma
  • Patent number: 7094798
    Abstract: This invention relates to pyrrolocarbazole derivatives according formula I wherein R1, R2, R7, R8, R9, X and Y are as defined in the specification wherein said derivatives specifically inhibit one or both of the checkpoint kinases Wee1 and Chk1
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: August 22, 2006
    Assignee: Pfizer Inc
    Inventors: Richard John Booth, Ellen Myra Dobrusin, Alan Kraker, Lorna Helen Mitchell, William Alexander Denny, Jeffrey Bruce Smaill, Andrew Mark Thompson, Florence Oliver Joseph McCarthy, Ho Huat Lee, Brian Desmond Palmer
  • Publication number: 20030186987
    Abstract: Described are heterocyclic pyrimidine derivatives and a method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof, a compound of the formula: 1
    Type: Application
    Filed: July 24, 2002
    Publication date: October 2, 2003
    Inventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson
  • Patent number: 6596726
    Abstract: Described are compounds of the following formula and a method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof, a compound of the formula: wherein the formula terms are described in the specification and wherein the members in the aforementioned structure are defined in the specification.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: July 22, 2003
    Assignee: Warner Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson, Howard Daniel Hollis Showalter
  • Patent number: 6455534
    Abstract: Described are compounds and a method of inhibiting epidermal growth factor receptor tyrosine kinase by treating, with an effective inhibiting amount, a mammal, in need thereof, a compound of Formula II: where: one of A or E is nitrogen, with remaining atoms carbon; X=O, S, NH or NR7, such that R7=lower alkyl (1-4 carbon atoms), OH, NH2, lower alkoxy (1-4 carbon atoms) or lower monoalkylamino (1-4 carbon atoms). Other terms are described in the specification.
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: September 24, 2002
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson
  • Publication number: 20010027197
    Abstract: Described are compounds and a method of inhibiting epidermal growth factor receptor tyrosine kinase by treating, with an effective inhibiting amount, a mammal, in need thereof, a compound of Formula II: 1
    Type: Application
    Filed: April 2, 2001
    Publication date: October 4, 2001
    Inventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson
  • Patent number: 6265410
    Abstract: Described are compositions and a method of inhibiting epidermal growth factor receptor tyrosine kinase by treating, with an effective inhibiting amount, a mammal, in need thereof, a compound of Formula II: where: any two continguous positions in positions A-E taken together can be a single heteroatom selected from the group consisting of nitrogen, oxygen or sulfur, in which case the other two remaining atoms must be carbon; the remaining substituents are disclosed in the specification
    Type: Grant
    Filed: November 13, 1998
    Date of Patent: July 24, 2001
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson
  • Patent number: 6150359
    Abstract: This invention relates to the inhibition of protein tyrosine kinase (PTK) and cell cycle kinase mediated cellular proliferation. More specifically, this invention relates to naphthyridinones and their use in inhibiting cellular proliferation and PTK or cell cycle kinase enzymatic activity.
    Type: Grant
    Filed: January 26, 2000
    Date of Patent: November 21, 2000
    Assignee: Warner-Lambert Company
    Inventors: Mark Robert Barvian, William Alexander Denny, Ellen Myra Dobrusin, James Marino Hamby, Howard Daniel Hollis Showalter, Andrew Mark Thompson, Roy Thomas Winters, Zhipei Wu
  • Patent number: 6084095
    Abstract: Novel 4-substituted amino pyrido [3,2-d]pyrimidine inhibitors of epidermal growth factor receptor family of tyrosine kinases are described, as well as pharmaceutical compositions of the same, which are useful in treating proliferative diseases such as cancer, synovial pannus invasion in arthritis, psoriasis, vascular restenosis and angiogenesis and additionally useful in the treatment of pancreatitis and kidney disease as well as a contraceptive agent.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: July 4, 2000
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson
  • Patent number: 5679683
    Abstract: Novel 4-substituted amino benzothieno?3,2-d!pyrimidine and 4-substituted amino?2,3-d!pyrimidine inhibitors of epidermal growth factor receptor family of tyrosine kinases are described, as well as pharmaceutical compositions of the same, which are useful in treating proliferative diseases such as cancer, synovial pannus invasion in arthritis, psoriasis, vascular restenosis and angiogenesis and additionally useful in the treatment of pancreatitis and kidney disease as well as a contraceptive agent.
    Type: Grant
    Filed: December 23, 1994
    Date of Patent: October 21, 1997
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson, Howard Daniel Hollis Showalter
  • Patent number: 5654307
    Abstract: Novel 4-substituted amino pyrido pyrimidine and 4-substituted amino pyrido pyrimidine inhibitors of epidermal growth factor receptor family of tyrosine kinase are described, as well as pharmaceutical compositions of the same, which are useful in treating proliferative diseases such as cancer, synovial pannus invasion in arthritis, psoriasis, vascular restenosis and angiogenesis and additionally useful in the treatment of pancreatitis and kidney disease as well as a contraceptive agent.
    Type: Grant
    Filed: December 23, 1994
    Date of Patent: August 5, 1997
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson